Study on Glycaemic Status and Lipid Profile in Type 2 Diabetic Patients Attending Mymensingh Medical College Hospital, Mymensingh.
Recent increases in the incidence of diabetes in developing countries have been associated with complications resulting in mortality and morbidity. A case control study of 120 subjects attending out patient department of Mymensingh Medical College, Mymensingh was done with an aim to evaluate alteration of serum lipid profile and HbA1c in type 2 diabetic patients and compare with age matched healthy control. Of the total cases, 60 were Type 2 diabetic patients and 60 were apparently healthy persons recruited for the study. These patients and control subjects were classified as male (50%) and female (50%). Fasting lipid profile and HbA1c% were measured by following the standard laboratory methods. The study subjects had relatively poor glycemic control. The mean HbA1c was 9.21±1.19% in diabetes patient and 4.71±0.60% was in control. The mean fasting blood glucose level was 10.18±1.56mmol/L in diabetes patient and 4.51±0.48mmol/L in control. The mean total cholesterol, triacylglycerols, HDL-C & LDL-C were 211.93±11.83mg/dl, 156.90±7.96mg/dl, 35.20±3.17mg/dl & 133.20±3.99mg/dl in diabetes patient accordingly and the mean total cholesterol, triacylglycerols, HDL-C & LDL-C were 159.72±4.89mg/dl, 117.45±12.97mg/dl, 44.23±2.75mg/dl & 92.15±5.67mg/dl in control group accordingly. The study revealed that the most common abnormality seen was decreased serum HDL-Cholesterol levels (91.67%). Hypertriglyceridaemia present in 81.67% patients, 78.34% had high LDL-Cholesterol and 73.34% had hypercholesteromia. Diabetic males had significantly higher levels of total cholesterol and LDL-Cholesterol compared to diabetic females and diabetic females had significantly lower levels of HDL-Cholesterol compared to diabetic males. It was concluded from the results of this study that, diabetic patients are more prone to develop dyslipidaemia. Thus early diagnosis of dyslipidemia and good glycaemic control can be used as a preventive measure for the development of cardiovascular disease (CVD) in type 2 diabetics.